200 related articles for article (PubMed ID: 34493823)
1. Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer.
Zong L; Mo S; Sun Z; Lu Z; Yu S; Chen J; Xiang Y
Mod Pathol; 2022 Feb; 35(2):266-273. PubMed ID: 34493823
[TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
3. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
[TBL] [Abstract][Full Text] [Related]
4. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
[TBL] [Abstract][Full Text] [Related]
6. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
7. Expression of the immune checkpoint VISTA in breast cancer.
Zong L; Mo S; Yu S; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1437-1446. PubMed ID: 32266446
[TBL] [Abstract][Full Text] [Related]
8. B7-H4 Further Stratifies Patients With Endometrial Cancer Exhibiting a Nonspecific Molecular Profile.
Zong L; Yu S; Mo S; Sun Z; Lu Z; Chen J; Xiang Y
Arch Pathol Lab Med; 2023 Nov; 147(11):1288-1297. PubMed ID: 36669510
[TBL] [Abstract][Full Text] [Related]
9. Expression of B7 family checkpoint proteins in cervical cancer.
Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma.
Zhang Z; Li M; Wang J; Liu M; Chen H; Lou Y; Wang Y; Sun Q; Zhu D; Li P; Bi Y
Endocr Relat Cancer; 2022 May; 29(7):403-413. PubMed ID: 35521773
[TBL] [Abstract][Full Text] [Related]
11. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
12. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
Zong L; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Jan; 69(1):33-42. PubMed ID: 31781843
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
15. VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
Jlassi A; Manai M; Morjen M; Sahraoui G; Elasmi Allal M; ELBini-Dhouib I; Naija L; Charfi L; Rejaibi R; Ben Ahmed M; Marrakchi N; Srairi-Abid N; Mezlini A; Manai M; Mrad K; Doghri R
PLoS One; 2023; 18(3):e0278849. PubMed ID: 36952478
[TBL] [Abstract][Full Text] [Related]
16. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma.
Wu L; Deng WW; Huang CF; Bu LL; Yu GT; Mao L; Zhang WF; Liu B; Sun ZJ
Cancer Immunol Immunother; 2017 May; 66(5):627-636. PubMed ID: 28236118
[TBL] [Abstract][Full Text] [Related]
17. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
Vagios S; Doulgeraki T; Giannikaki E; Kavoura E; Papadimitriou C; Gakiopoulou H; Pavlakis K
Anticancer Res; 2020 Mar; 40(3):1669-1676. PubMed ID: 32132073
[TBL] [Abstract][Full Text] [Related]
18. Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors.
Mo S; Zong L; Chen X; Ban X; Li M; Lu Z; Yu S; Chen J
Arch Pathol Lab Med; 2023 Feb; 147(2):193-201. PubMed ID: 35671167
[TBL] [Abstract][Full Text] [Related]
19. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
20. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]